GTBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GT Biopharma Inc (GTBP) is not a strong buy for a beginner investor with a long-term focus at this time. The stock lacks significant positive catalysts, has weak financial performance, and no recent trading signals from Intellectia Proprietary Trading Signals. While analysts maintain a Buy rating with a reduced price target, the company's financials and lack of immediate growth drivers make it a speculative investment. A hold is recommended until more favorable conditions or catalysts emerge.
The stock's MACD is slightly positive, indicating mild bullish momentum, but the RSI is neutral at 46.408, showing no clear trend. Moving averages are converging, and the stock is trading near its pivot level of 0.448, with support at 0.413 and resistance at 0.482. Overall, the technical indicators suggest a lack of strong directional movement.
Analysts maintain a Buy rating despite lowering the price target.
The company's financial performance remains weak, with no revenue and significant net losses. The stock has no recent news or significant trading activity from insiders, hedge funds, or Congress. Analysts have reduced the price target from $8 to $3, citing increased dilution and long timelines for data readouts.
In 2025/Q4, the company reported no revenue and a net loss of -$28.9M, though the loss improved YoY. EPS increased to -2.23, up 33.53% YoY, but the financials remain weak overall.
Analysts maintain a Buy rating but have lowered the price target from $8 to $3, citing increased dilution and long timelines for clinical trial data. The company has sufficient cash to fund operations through 2026, but the outlook is speculative with no near-term catalysts.
